VKTX vs LLY Stock Comparison: AI Score, Valuation, Performance and Upside
Viking Therapeutics is a binary, clinical-stage bet on a next-generation obesity drug with no approved revenue yet, while Eli Lilly is the commercially dominant incumbent already generating tens of billions from approved GLP-1 therapies. The better stock depends on whether an investor wants high-risk, high-reward exposure to a potential obesity-drug breakthrough or proven, diversified pharma cash flow.
Use this VKTX vs LLY comparison to weigh clinical-stage binary risk against commercial-stage compounding. VKTX could deliver outsized returns on positive Phase 3 data or an acquisition, but could also see a sharp drawdown on a trial miss; LLY offers lower-variance exposure to the same obesity-drug megatrend through an already-approved, scaled franchise.
LLY holds the edge across 4 of 5 key metrics in this comparison. LLY leads on both 1-year return (+51.42%) and forward P/E quality (24.87x vs -7.76x for VKTX), a relatively favorable combination of momentum and valuation. Analyst consensus implies meaningfully more upside for VKTX (+175.81%) than for LLY (+11.96%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want high-risk, high-reward exposure to a clinical-stage obesity drug candidate
- Believe VK2735's efficacy and oral-formulation optionality can differentiate it from approved therapies
- Are comfortable with binary trial-readout risk and no current product revenue
- See takeover potential as an added source of upside if a larger pharma acquires Viking
- Want proven, already-approved GLP-1/GIP revenue rather than clinical-stage binary risk
- Value pipeline diversification across obesity, diabetes, oncology, and neuroscience
- Prefer a mega-cap pharma balance sheet and dividend over a pre-revenue biotech
- Believe Lilly's manufacturing scale and pipeline depth will preserve leadership even as competitors like Viking advance
| Metric | VKTX | LLY |
|---|---|---|
| AI scorei | 43.5 | 76.6 |
| AI ranki | #754 | #22 |
| Latest closei | $27.37 | $1,251.61 |
| 1M returni | -8.61% | +10.17% |
| 3M returni | -24.75% | +7.05% |
| 6M returni | -22.92% | +38.45% |
| 1Y returni | -22.07% | +51.42% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | VKTX | LLY |
|---|---|---|
| 1Y ago | $7.88K (-21.2%) started 2025-10-16 | $15.28K (+52.8%) started 2025-10-16 |
| 5Y ago | $46.71K (+367.1%) started 2021-10-18 | $56.41K (+464.1%) started 2021-10-18 |
| 10Y ago | $246.58K (+2365.8%) started 2016-10-17 | $216.68K (+2066.8%) started 2016-10-17 |
Hypothetical — past performance does not guarantee future results.
| Metric | VKTX | LLY |
|---|---|---|
| Market capi | $3.91B | $1.05T |
| Trailing P/Ei | N/A | 39.36 |
| Forward P/Ei | -7.76 | 24.87 |
| Price/Salesi | N/A | 14.10 |
| EV/Revenuei | N/A | 13.72 |
| Analyst targeti | $92.39 | $1,315.04 |
| Target upsidei | +175.81% | +11.96% |
| Metric | VKTX | LLY |
|---|---|---|
| Revenue growthi | N/A | 47.70% |
| Earnings growthi | N/A | 26.20% |
| EPS growthi | N/A | +26.20% |
| FCF margini | N/A | +13.89% |
| Operating margini | 0.00% | 54.22% |
| Profit margini | 0.00% | 33.53% |
| ROIC proxyi | -88.85% | 102.29% |
| Return on equityi | -88.85% | 102.29% |
| Dividend yieldi | N/A | 0.59% |
| Payout ratioi | N/A | 21.69% |
| Dividend growth streaki | N/A | No increase yet |
| Betai | 0.69 | 0.51 |
| Debt/equityi | 1.00 | 162.07 |
| Current ratioi | 4.72 | 1.35 |
| Quick ratioi | 4.58 | 0.68 |
Over the past year, VKTX and LLY have moved weakly in the same direction (correlation of 0.27), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | VKTX | LLY |
|---|---|---|---|
| 1Y | Growthi | -21.19% | +52.75% |
| CAGRi | -21.22% | +52.86% | |
| Volatilityi | 68.46% | 34.68% | |
| Sharpe ratioi | -0.09 | 1.27 | |
| Sortino ratioi | -0.15 | 2.12 | |
| Max drawdowni | 39.54% | 23.31% | |
| Current drawdowni | 35.03% | 2.24% | |
| Avg drawdowni | 17.95% | 6.90% | |
| Ulcer Indexi | 19.90% | 8.82% | |
| Max daily dropi | 11.76% | 7.79% | |
| Max wkly dropi | 22.13% | 8.60% | |
| 5Y | Growthi | +367.06% | +443.42% |
| CAGRi | +36.16% | +40.34% | |
| Volatilityi | 103.41% | 32.75% | |
| Sharpe ratioi | 0.68 | 1.06 | |
| Sortino ratioi | 1.38 | 1.64 | |
| Max drawdowni | 78.86% | 34.48% | |
| Current drawdowni | 71.04% | 2.24% | |
| Avg drawdowni | 45.60% | 7.51% | |
| Ulcer Indexi | 50.79% | 10.26% | |
| Max daily dropi | 42.12% | 14.14% | |
| Max wkly dropi | 38.89% | 17.93% | |
| 10Y | Growthi | +2365.77% | +1748.09% |
| CAGRi | +37.80% | +33.88% | |
| Volatilityi | 97.85% | 30.59% | |
| Sharpe ratioi | 0.69 | 0.96 | |
| Sortino ratioi | 1.41 | 1.49 | |
| Max drawdowni | 89.26% | 34.48% | |
| Current drawdowni | 71.04% | 2.24% | |
| Avg drawdowni | 50.83% | 6.85% | |
| Ulcer Indexi | 56.40% | 9.24% | |
| Max daily dropi | 42.12% | 14.14% | |
| Max wkly dropi | 38.89% | 17.93% |
| Category | VKTX | LLY |
|---|---|---|
| Company | Viking Therapeutics, Inc. | Eli Lilly and Company |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - General |
| Core business | Clinical-stage biopharmaceutical company developing VK2735, a dual GLP-1/GIP receptor agonist for obesity in both subcutaneous and oral formulations, currently advancing through Phase 3 trials, with no approved commercial products yet. | Global pharmaceutical company with a leading, commercially approved GLP-1/GIP franchise (Zepbound, Mounjaro) generating tens of billions in annual revenue, plus a broad late-stage pipeline including oral GLP-1 orforglipron. |
| Investor focus | Phase 3 trial readouts for VK2735, oral formulation bioavailability and dosing progress, cash runway, and acquisition speculation given the crowded incretin race. | Zepbound/Mounjaro volume and pricing, manufacturing capacity expansion, oral GLP-1 launch trajectory, and pipeline diversification beyond incretins. |
- VK2735 has shown competitive weight-loss efficacy data in earlier-stage trials relative to approved GLP-1 therapies
- Dual subcutaneous and oral formulation strategy could address different patient preference and adherence needs
- Frequently cited as a potential acquisition target for larger pharma seeking obesity-pipeline exposure
- Already-approved, commercially scaled GLP-1/GIP franchise generating substantial recurring revenue
- Deep, diversified late-stage pipeline reduces single-drug dependence relative to a clinical-stage peer
- Massive manufacturing and distribution infrastructure that a clinical-stage company like Viking cannot replicate independently
- Binary clinical trial risk — Phase 3 data misses or delays could sharply reduce valuation given no revenue base
- No approved products means the company remains pre-commercial and dependent on capital markets or a partner/acquirer
- Intensifying competition from Lilly, Novo Nordisk, and other well-funded incretin programs racing toward the same indications
- Manufacturing capacity and supply chain execution as demand continues to outstrip production in many markets
- Pricing and reimbursement pressure from PBMs, Medicare negotiation, and compounded-drug competition
- Competitive threat from next-generation obesity candidates, including Viking's VK2735, that could erode future market share
Compare more than two at a time
This page is a fixed writeup on VKTX and LLY. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside VKTX and LLY, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.